Show simple item record

dc.contributor.authorCubo Delgado, Esther 
dc.date.accessioned2024-03-06T10:45:56Z
dc.date.available2024-03-06T10:45:56Z
dc.date.issued2010-09
dc.identifier.urihttp://hdl.handle.net/10259/8762
dc.description.abstractIn the absence of a cure, the primary goals in managing Parkinson’s disease (PD) are to preserve functionality and health-related quality of life (HRQoL). Current therapeutic strategies for PD include symptomatic treatment and are primarily focused on replacing dopamine in the brain. Dopamine agonists can be used as an alternative initial levodopa therapy, to delay the onset of motor complications, but at the expense of more dopaminergic adverse effects; poorer control of motor symptoms; and increased cost. In PD, treatment effects and costs accumulate over time; hence the choice of time horizon in cost-effectiveness analysis can be particularly important. Pharmaceutical expenditures have grown rapidly in recent decades and now total nearly 10% of all health care costs. The main approach to treat PD at the present time is to advance knowledge of the efficacy, to reduce long-term complications associated with treatment, and to improve patient HRQoL and society burden. The implementation of cost-effectiveness studies, including the societal perspective, should be considered as an outcome of new therapy strategies, which would be helpful to health care decision makers.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherTaylor & Francis Groupen
dc.relation.ispartofClinicoEconomics and Outcomes Research. 2010, V. 2, n. 1, p. 127-134en
dc.rightsAttribution-NonCommercial 3.0 Unported*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/*
dc.subjectParkinson’s diseaseen
dc.subjectCostsen
dc.subjectHealth-related quality of lifeen
dc.subject.otherSistema nervioso-Enfermedadeses
dc.subject.otherNervous system-Diseasesen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.titlePharmacotherapy in the management of early Parkinson’s disease: cost-effectiveness and patient acceptabilityen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.2147/CEOR.S11996es
dc.identifier.doi10.2147/CEOR.S11996
dc.identifier.essn1178-6981
dc.journal.titleClinicoEconomics and Outcomes Researchen
dc.volume.number2es
dc.issue.number1es
dc.page.initial127es
dc.page.final134es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record